Canine Pipeline

Parvovirus in Dogs


KIND-030 – Parvovirus in dogs

KIND-030, a monoclonal antibody targeting canine parvovirus (CPV), is being pursued for two indications: Prophylactic therapy to prevent clinical signs of CPV infection, and treatment of established CPV infection.

Positive results from pivotal efficacy study for the prophylactic indication. All placebo-control dogs developed parvovirus infection, while none of the KIND-030 dogs developed the disease. Mortality benefit in treated group also observed.

Prevalence

CPV is the most significant cause of enteric virus infecting dogs worldwide. Puppies between 10 and 12 weeks of age are particularly vulnerable to CPV because the protective effect of their maternally derived antibodies wanes or there is lack of response to immunization due to maternal antibody interference.¹ Banfield medical records estimate there are approximately 250,000 CPV cases in the United States each year, excluding emergency rooms, shelters, or undiagnosed cases. This does not include the other puppies and dogs that are potentially exposed to the virus.²

Disease Burden

Despite 40 years of research, there remains a high unmet medical need for an effective targeted therapeutic for CPV. There are currently no approved or unapproved treatments for CPV, and mortality rates are reportedly as high as 91% if untreated. Today, management of CPV infection is largely supportive.^3,4 Owners spend up to thousands of dollars per puppy in supportive care for CPV, with average cost of $1,200. If approved, KIND-030 would work in conjunction with vaccination protocols and would not replace the need for vaccination.

Cost Burden

Hospitalization is generally recommended,⁵ which can be cost prohibitive for some owners.⁶ Within a veterinary practice, treating CPV infection requires implementation of strict isolation and decontamination protocols to minimize spread of the virus, which adds to the cost of treatment.⁷ Despite 40 years of research, there remains a high unmet medical need for an effective targeted therapeutic for CPV.

Near-term Catalysts

Completion of the pivotal efficacy study for the treatment of established parvovirus infection is expected in the first quarter of 2021. KindredBio will provide an update on the timing of KIND-030's expected approval at the time of announcing the company's fourth quarter 2020 results.

References:

1. Altman KD, Kelman M, Ward MP. Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure? Vet Microbiol. 2017; 210:8-16.
2. Banfield Pet Hospital. State of Pet Health Report(tm) 2014. Available at: https://www.banfield.com/Banfield/media/PDF/Downloads/soph/Banfield-State-of-Pet-Health-Report_2014.pdf [Access date: March 17, 2020].
3. Wilson S, Illambas J, Siedek E, et al. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c. Vaccine. 2014;32(42):5420-5424.
4. Greene CE, Decaro N. Canine viral enteritis. In: Green CE, ed. Infectious Diseases of the Dog and Cat, 4th ed. St. Louis, MO: Elsevier Saunders; 2012:67-80.
5. Venn EC, Preisner K, Boscan PL, et al. Evaluation of an outpatient protocol in the treatment of canine parvoviral enteritis. J Vet Emerg Crit Care (San Antonio). 2017;27(1):52-65.
6. Kelman M, Ward MP, Barrs VR, Norris JM. The geographic distribution and financial impact of canine parvovirus in Australia. Transbound Emerg Dis. 2019;66(1):299-311.
7. Nandi S, Kumar M. Canine parvovirus: current perspective. Indian J Virol. 2010;21(1):31-44.

US-CORP-2000022 MAR-20